Medtronic, Inc.(MDT: Quote), Monday said its AdaptivCRT technology reduced nearly 50 percent atrial fibrillation or AF risk in heart failure patients. The results were presented today at a clinical trial at the Heart Failure Society of America’s meeting, the company said. The AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators or CRT-Ds that continually adjusts therapy to a patient’s natural heart rhythms and minimizes the amount of unnecessary right ventricular or RV pacing.
Help employers find you! Check out all the jobs and post your resume.
